Print this page    •   Back to Web version of article

The Body Covers: The 36th Annual Meeting of the Infectious Diseases Society of America

Abstract 464: Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity

Coverage provided by Frederick L. Altice, M.D.

November 14, 1998

Based on previous efficacy data on other dual protease inhibitor combinations, this study combining the use of IDV with NFV was undertaken to determine the PK and antiviral activity of the combination that allows for favorable twice daily dosing of IDV. A three part PK study design using varying doses of IDV and NFV was undertaken. For the 21 male study subjects enrolled, 58% were antiretroviral naïve and 42% were NRTI-experienced. The median CD4 count was 259 (range 120-568) and the median viral load was 50,500 copies/mL (range 9,090-316,170). Results from the PK data demonstrated that the AUC, trough, and Cmax levels of IDV 1,200 mg BID when co-administered with NFV 1,250 mg BID was similar to historical controls using IDV 800 mg q8h. IDV, however, had no appreciable effect on NFV levels.

Of the 21 patients enrolled in the PK studies, 8 had discontinued the study; 5 because of increasing viral load, 2 for poor adherence, and one for rash. The authors report virologic and CD4 data on only the 13 who completed the study (on treatment analysis) for which 10 (77%) had VL<400 copies/mL and had an average 334 cell CD4 cell increase at week 68. Of the nine patients using the ultrasensitive VL assay at the end of the study, 8 were <50 copies/mL. The intention-to-treat analysis, though not reported by the authors, is less optimistic. Of the 21 enrolled study subjects, 10 (48%) had a VL<400 copies/mL. None of the patients had a dose-limiting toxicity, however the majority of reported adverse events were gastrointestinal: 6 (29%) had diarrhea, 4 (19%) had bloating/cramps, and 4 (14%) had nausea.

This article was provided by Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.